Protein-bound paclitaxel

Protein-bound paclitaxel
Combination of
Paclitaxel mitotic inhibitor
Albumin delivery vehicle
Clinical data
Trade names Abraxane
AHFS/Drugs.com FDA Professional Drug Information
Pregnancy cat.  ?
Legal status ℞-only (US)
Routes IV
Identifiers
ATC code  ?
 N(what is this?)  (verify)

Protein-bound paclitaxel is an injectable formulation of paclitaxel, a mitotic inhibitor drug used in the treatment of breast cancer.[1] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is sold in the United States under the trade name Abraxane by Abraxis Bioscience.[2]

This treatment was approved by the Food and Drug Administration in January 2005 for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[3]

Abraxane is a first in its class of drugs using nanoparticle albumin bound (nab) technology platform.[4]

In June 2010, positive results were published from a phase III trial in first-line non-small-cell lung cancer (NSCLC) when compared with Taxol (solvent-based paclitaxel).[5]

Total revenue from the sales of Abraxane for 2009 were $314.5 million.[5]

In 2010, Abraxis was acquired by Celgene, who now market Abraxane.[6]

References

  1. ^ "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=507751. 
  2. ^ "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. http://www.cancer.gov/cancertopics/druginfo/nanoparticlepaclitaxel. 
  3. ^ "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel. 
  4. ^ nab Technology
  5. ^ a b "Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC". 2010. http://www.genengnews.com/gen-news-highlights/abraxis-reports-phase-iii-success-with-abraxane-in-first-line-nsclc/81243495/. 
  6. ^ Celgene Completes Acquisition of Abraxis